Meeting
2013 ASCO Annual Meeting
A phase II study of oral metronomic combination therapy in relapsed epithelial ovarian cancer.
Authors
Sudeep Gupta
Tata Memorial Centre, Mumbai, India
Sudeep Gupta , Gautam Goyal , Jaya Ghosh , Bharatsinha Baburao Bhosale , Jyoti Bajpai , Amita Maheshwari , Rajendra Kerkar , Kedar Deodhar , Bharat Rekhi , Santosh Menon , Shripad Banavali
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 5554)
DOI
10.1200/jco.2013.31.15_suppl.5554
Abstract #
5554
Poster Bd #
46B
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Final report of randomized phase II study of two different outpatient setting regimens, vinorelbine (VNR) with cyclophosphamide (CPA) and temozolomide (TMZ) with etoposide (VP).
First Author: Atsushi Ogawa
Poster
2014 ASCO Annual Meeting
Etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine (EMA/CO) for males with HCG-expressing, chemorefractory germ cell tumors (GCT): Long-term efficacy and safety outcomes.
First Author: Daniele Raggi
Poster
2022 ASCO Genitourinary Cancers Symposium
GAMMA: Results from a phase II study for relapsed germ cell tumors using an oxaliplatin-based treatment regimen.
First Author: Kenrick Ng
Poster
2018 ASCO Annual Meeting
METRO-BIBF: Phase II, randomised, placebo controlled, multicentre, trial of low dose (metronomic) cyclophosphamide (MCy) with or without nintedanib in relapsed ovarian cancer (ROC).
First Author: Marcia Hall